TORONTO – Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on developing next-generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, commenced trading on the Canadian Securities Exchange effective at the open of business on Wednesday, December 23, 2020, under the symbol “MSET”.
James Lanthier, CEO of Mindset, commented, “I am excited to share this announcement as it represents a significant milestone for Mindset and our shareholders. Our portfolio of next-generation patent-pending drug candidates and our innovative process to efficiently synthesize pharmaceutical-grade psilocybin are unique technologies that have the potential to play a significant role in the growth of the emerging psychedelic medication market. With the proceeds from the closing of the Company’s recent private placement offering and the completion of Ontario Brain Institute investment, we are well funded to continue to advance and further develop our drug development and synthesis programs. We look forward to sharing additional updates around Mindset’s progress shortly.”
Mindset Pharma is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds.
We seek Safe Harbor.